Response to Letter Regarding Article, “Ventricular Phosphodiesterase-5 Expression Is Increased in Patients With Advanced Heart Failure and Contributes to Adverse Ventricular Remodeling After Myocardial Infarction in Mice”
- 13 October 2009
- journal article
- letter
- Published by Wolters Kluwer Health in Circulation
- Vol. 120 (15) , 138
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Cyclic GMP signaling in cardiovascular pathophysiology and therapeuticsPharmacology & Therapeutics, 2009
- cGMP signalling in pre- and post-conditioning: the role of mitochondriaCardiovascular Research, 2007
- Phosphodiesterase 5A Inhibition Induces Na + /H + Exchanger Blockade and Protection Against Myocardial InfarctionHypertension, 2007
- Sodium-Hydrogen Exchanger, Cardiac Overload, and Myocardial HypertrophyCirculation, 2007
- Cyclic GMP-dependent Protein Kinase Iα Attenuates Necrosis and Apoptosis Following Ischemia/Reoxygenation in Adult CardiomyocyteJournal of Biological Chemistry, 2006
- Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial KATP channels in rabbitsJournal of Molecular and Cellular Cardiology, 2006
- Single L-type Ca2+ channel regulation by cGMP-dependent protein kinase type I in adult cardiomyocytes from PKG I transgenic miceCardiovascular Research, 2003